Irritable Bowel Syndrome Treatment-EMEA Market Status and Trend Report 2013-2023
Report Summary
Irritable Bowel Syndrome Treatment-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Irritable Bowel Syndrome Treatment industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole EMEA and Regional Market Size of Irritable Bowel Syndrome Treatment 2013-2017, and development forecast 2018-2023
Main market players of Irritable Bowel Syndrome Treatment in EMEA, with company and product introduction, position in the Irritable Bowel Syndrome Treatment market
Market status and development trend of Irritable Bowel Syndrome Treatment by types and applications
Cost and profit status of Irritable Bowel Syndrome Treatment, and marketing status
Market growth drivers and challenges
The report segments the EMEA Irritable Bowel Syndrome Treatment market as:
EMEA Irritable Bowel Syndrome Treatment Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Europe
Middle East
Africa
EMEA Irritable Bowel Syndrome Treatment Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Lubiprostone
Linaclotide
Eluxadoline
Rifaximin
Ramosetron Hydrochloride
Others
EMEA Irritable Bowel Syndrome Treatment Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospital
Clinic
Home Care
EMEA Irritable Bowel Syndrome Treatment Market: Players Segment Analysis (Company and Product introduction, Irritable Bowel Syndrome Treatment Sales Volume, Revenue, Price and Gross Margin):
Abbott Laboratories
Synergy Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc.
Valeant Pharmaceuticals International, Inc.
Ardelyx, Inc.
Astellas Pharma Inc.
Novartis AG
GlaxoSmithKline plc.
Ironwood Pharmaceuticals, Inc.
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Irritable Bowel Syndrome Treatment-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Irritable Bowel Syndrome Treatment industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole EMEA and Regional Market Size of Irritable Bowel Syndrome Treatment 2013-2017, and development forecast 2018-2023
Main market players of Irritable Bowel Syndrome Treatment in EMEA, with company and product introduction, position in the Irritable Bowel Syndrome Treatment market
Market status and development trend of Irritable Bowel Syndrome Treatment by types and applications
Cost and profit status of Irritable Bowel Syndrome Treatment, and marketing status
Market growth drivers and challenges
The report segments the EMEA Irritable Bowel Syndrome Treatment market as:
EMEA Irritable Bowel Syndrome Treatment Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Europe
Middle East
Africa
EMEA Irritable Bowel Syndrome Treatment Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Lubiprostone
Linaclotide
Eluxadoline
Rifaximin
Ramosetron Hydrochloride
Others
EMEA Irritable Bowel Syndrome Treatment Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospital
Clinic
Home Care
EMEA Irritable Bowel Syndrome Treatment Market: Players Segment Analysis (Company and Product introduction, Irritable Bowel Syndrome Treatment Sales Volume, Revenue, Price and Gross Margin):
Abbott Laboratories
Synergy Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc.
Valeant Pharmaceuticals International, Inc.
Ardelyx, Inc.
Astellas Pharma Inc.
Novartis AG
GlaxoSmithKline plc.
Ironwood Pharmaceuticals, Inc.
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF IRRITABLE BOWEL SYNDROME TREATMENT
1.1 Definition of Irritable Bowel Syndrome Treatment in This Report
1.2 Commercial Types of Irritable Bowel Syndrome Treatment
1.2.1 Lubiprostone
1.2.2 Linaclotide
1.2.3 Eluxadoline
1.2.4 Rifaximin
1.2.5 Ramosetron Hydrochloride
1.2.6 Others
1.3 Downstream Application of Irritable Bowel Syndrome Treatment
1.3.1 Hospital
1.3.2 Clinic
1.3.3 Home Care
1.4 Development History of Irritable Bowel Syndrome Treatment
1.5 Market Status and Trend of Irritable Bowel Syndrome Treatment 2013-2023
1.5.1 EMEA Irritable Bowel Syndrome Treatment Market Status and Trend 2013-2023
1.5.2 Regional Irritable Bowel Syndrome Treatment Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Irritable Bowel Syndrome Treatment in EMEA 2013-2017
2.2 Consumption Market of Irritable Bowel Syndrome Treatment in EMEA by Regions
2.2.1 Consumption Volume of Irritable Bowel Syndrome Treatment in EMEA by Regions
2.2.2 Revenue of Irritable Bowel Syndrome Treatment in EMEA by Regions
2.3 Market Analysis of Irritable Bowel Syndrome Treatment in EMEA by Regions
2.3.1 Market Analysis of Irritable Bowel Syndrome Treatment in Europe 2013-2017
2.3.2 Market Analysis of Irritable Bowel Syndrome Treatment in Middle East 2013-2017
2.3.3 Market Analysis of Irritable Bowel Syndrome Treatment in Africa 2013-2017
2.4 Market Development Forecast of Irritable Bowel Syndrome Treatment in EMEA 2018-2023
2.4.1 Market Development Forecast of Irritable Bowel Syndrome Treatment in EMEA 2018-2023
2.4.2 Market Development Forecast of Irritable Bowel Syndrome Treatment by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of Irritable Bowel Syndrome Treatment in EMEA by Types
3.1.2 Revenue of Irritable Bowel Syndrome Treatment in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Irritable Bowel Syndrome Treatment in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Irritable Bowel Syndrome Treatment in EMEA by Downstream Industry
4.2 Demand Volume of Irritable Bowel Syndrome Treatment by Downstream Industry in Major Countries
4.2.1 Demand Volume of Irritable Bowel Syndrome Treatment by Downstream Industry in Europe
4.2.2 Demand Volume of Irritable Bowel Syndrome Treatment by Downstream Industry in Middle East
4.2.3 Demand Volume of Irritable Bowel Syndrome Treatment by Downstream Industry in Africa
4.3 Market Forecast of Irritable Bowel Syndrome Treatment in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF IRRITABLE BOWEL SYNDROME TREATMENT
5.1 EMEA Economy Situation and Trend Overview
5.2 Irritable Bowel Syndrome Treatment Downstream Industry Situation and Trend Overview
CHAPTER 6 IRRITABLE BOWEL SYNDROME TREATMENT MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of Irritable Bowel Syndrome Treatment in EMEA by Major Players
6.2 Revenue of Irritable Bowel Syndrome Treatment in EMEA by Major Players
6.3 Basic Information of Irritable Bowel Syndrome Treatment by Major Players
6.3.1 Headquarters Location and Established Time of Irritable Bowel Syndrome Treatment Major Players
6.3.2 Employees and Revenue Level of Irritable Bowel Syndrome Treatment Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 IRRITABLE BOWEL SYNDROME TREATMENT MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Abbott Laboratories
7.1.1 Company profile
7.1.2 Representative Irritable Bowel Syndrome Treatment Product
7.1.3 Irritable Bowel Syndrome Treatment Sales, Revenue, Price and Gross Margin of Abbott Laboratories
7.2 Synergy Pharmaceuticals, Inc.
7.2.1 Company profile
7.2.2 Representative Irritable Bowel Syndrome Treatment Product
7.2.3 Irritable Bowel Syndrome Treatment Sales, Revenue, Price and Gross Margin of Synergy Pharmaceuticals, Inc.
7.3 Sucampo Pharmaceuticals, Inc.
7.3.1 Company profile
7.3.2 Representative Irritable Bowel Syndrome Treatment Product
7.3.3 Irritable Bowel Syndrome Treatment Sales, Revenue, Price and Gross Margin of Sucampo Pharmaceuticals, Inc.
7.4 Valeant Pharmaceuticals International, Inc.
7.4.1 Company profile
7.4.2 Representative Irritable Bowel Syndrome Treatment Product
7.4.3 Irritable Bowel Syndrome Treatment Sales, Revenue, Price and Gross Margin of Valeant Pharmaceuticals International, Inc.
7.5 Ardelyx, Inc.
7.5.1 Company profile
7.5.2 Representative Irritable Bowel Syndrome Treatment Product
7.5.3 Irritable Bowel Syndrome Treatment Sales, Revenue, Price and Gross Margin of Ardelyx, Inc.
7.6 Astellas Pharma Inc.
7.6.1 Company profile
7.6.2 Representative Irritable Bowel Syndrome Treatment Product
7.6.3 Irritable Bowel Syndrome Treatment Sales, Revenue, Price and Gross Margin of Astellas Pharma Inc.
7.7 Novartis AG
7.7.1 Company profile
7.7.2 Representative Irritable Bowel Syndrome Treatment Product
7.7.3 Irritable Bowel Syndrome Treatment Sales, Revenue, Price and Gross Margin of Novartis AG
7.8 GlaxoSmithKline plc.
7.8.1 Company profile
7.8.2 Representative Irritable Bowel Syndrome Treatment Product
7.8.3 Irritable Bowel Syndrome Treatment Sales, Revenue, Price and Gross Margin of GlaxoSmithKline plc.
7.9 Ironwood Pharmaceuticals, Inc.
7.9.1 Company profile
7.9.2 Representative Irritable Bowel Syndrome Treatment Product
7.9.3 Irritable Bowel Syndrome Treatment Sales, Revenue, Price and Gross Margin of Ironwood Pharmaceuticals, Inc.
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF IRRITABLE BOWEL SYNDROME TREATMENT
8.1 Industry Chain of Irritable Bowel Syndrome Treatment
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF IRRITABLE BOWEL SYNDROME TREATMENT
9.1 Cost Structure Analysis of Irritable Bowel Syndrome Treatment
9.2 Raw Materials Cost Analysis of Irritable Bowel Syndrome Treatment
9.3 Labor Cost Analysis of Irritable Bowel Syndrome Treatment
9.4 Manufacturing Expenses Analysis of Irritable Bowel Syndrome Treatment
CHAPTER 10 MARKETING STATUS ANALYSIS OF IRRITABLE BOWEL SYNDROME TREATMENT
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Irritable Bowel Syndrome Treatment in This Report
1.2 Commercial Types of Irritable Bowel Syndrome Treatment
1.2.1 Lubiprostone
1.2.2 Linaclotide
1.2.3 Eluxadoline
1.2.4 Rifaximin
1.2.5 Ramosetron Hydrochloride
1.2.6 Others
1.3 Downstream Application of Irritable Bowel Syndrome Treatment
1.3.1 Hospital
1.3.2 Clinic
1.3.3 Home Care
1.4 Development History of Irritable Bowel Syndrome Treatment
1.5 Market Status and Trend of Irritable Bowel Syndrome Treatment 2013-2023
1.5.1 EMEA Irritable Bowel Syndrome Treatment Market Status and Trend 2013-2023
1.5.2 Regional Irritable Bowel Syndrome Treatment Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Irritable Bowel Syndrome Treatment in EMEA 2013-2017
2.2 Consumption Market of Irritable Bowel Syndrome Treatment in EMEA by Regions
2.2.1 Consumption Volume of Irritable Bowel Syndrome Treatment in EMEA by Regions
2.2.2 Revenue of Irritable Bowel Syndrome Treatment in EMEA by Regions
2.3 Market Analysis of Irritable Bowel Syndrome Treatment in EMEA by Regions
2.3.1 Market Analysis of Irritable Bowel Syndrome Treatment in Europe 2013-2017
2.3.2 Market Analysis of Irritable Bowel Syndrome Treatment in Middle East 2013-2017
2.3.3 Market Analysis of Irritable Bowel Syndrome Treatment in Africa 2013-2017
2.4 Market Development Forecast of Irritable Bowel Syndrome Treatment in EMEA 2018-2023
2.4.1 Market Development Forecast of Irritable Bowel Syndrome Treatment in EMEA 2018-2023
2.4.2 Market Development Forecast of Irritable Bowel Syndrome Treatment by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of Irritable Bowel Syndrome Treatment in EMEA by Types
3.1.2 Revenue of Irritable Bowel Syndrome Treatment in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Irritable Bowel Syndrome Treatment in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Irritable Bowel Syndrome Treatment in EMEA by Downstream Industry
4.2 Demand Volume of Irritable Bowel Syndrome Treatment by Downstream Industry in Major Countries
4.2.1 Demand Volume of Irritable Bowel Syndrome Treatment by Downstream Industry in Europe
4.2.2 Demand Volume of Irritable Bowel Syndrome Treatment by Downstream Industry in Middle East
4.2.3 Demand Volume of Irritable Bowel Syndrome Treatment by Downstream Industry in Africa
4.3 Market Forecast of Irritable Bowel Syndrome Treatment in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF IRRITABLE BOWEL SYNDROME TREATMENT
5.1 EMEA Economy Situation and Trend Overview
5.2 Irritable Bowel Syndrome Treatment Downstream Industry Situation and Trend Overview
CHAPTER 6 IRRITABLE BOWEL SYNDROME TREATMENT MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of Irritable Bowel Syndrome Treatment in EMEA by Major Players
6.2 Revenue of Irritable Bowel Syndrome Treatment in EMEA by Major Players
6.3 Basic Information of Irritable Bowel Syndrome Treatment by Major Players
6.3.1 Headquarters Location and Established Time of Irritable Bowel Syndrome Treatment Major Players
6.3.2 Employees and Revenue Level of Irritable Bowel Syndrome Treatment Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 IRRITABLE BOWEL SYNDROME TREATMENT MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Abbott Laboratories
7.1.1 Company profile
7.1.2 Representative Irritable Bowel Syndrome Treatment Product
7.1.3 Irritable Bowel Syndrome Treatment Sales, Revenue, Price and Gross Margin of Abbott Laboratories
7.2 Synergy Pharmaceuticals, Inc.
7.2.1 Company profile
7.2.2 Representative Irritable Bowel Syndrome Treatment Product
7.2.3 Irritable Bowel Syndrome Treatment Sales, Revenue, Price and Gross Margin of Synergy Pharmaceuticals, Inc.
7.3 Sucampo Pharmaceuticals, Inc.
7.3.1 Company profile
7.3.2 Representative Irritable Bowel Syndrome Treatment Product
7.3.3 Irritable Bowel Syndrome Treatment Sales, Revenue, Price and Gross Margin of Sucampo Pharmaceuticals, Inc.
7.4 Valeant Pharmaceuticals International, Inc.
7.4.1 Company profile
7.4.2 Representative Irritable Bowel Syndrome Treatment Product
7.4.3 Irritable Bowel Syndrome Treatment Sales, Revenue, Price and Gross Margin of Valeant Pharmaceuticals International, Inc.
7.5 Ardelyx, Inc.
7.5.1 Company profile
7.5.2 Representative Irritable Bowel Syndrome Treatment Product
7.5.3 Irritable Bowel Syndrome Treatment Sales, Revenue, Price and Gross Margin of Ardelyx, Inc.
7.6 Astellas Pharma Inc.
7.6.1 Company profile
7.6.2 Representative Irritable Bowel Syndrome Treatment Product
7.6.3 Irritable Bowel Syndrome Treatment Sales, Revenue, Price and Gross Margin of Astellas Pharma Inc.
7.7 Novartis AG
7.7.1 Company profile
7.7.2 Representative Irritable Bowel Syndrome Treatment Product
7.7.3 Irritable Bowel Syndrome Treatment Sales, Revenue, Price and Gross Margin of Novartis AG
7.8 GlaxoSmithKline plc.
7.8.1 Company profile
7.8.2 Representative Irritable Bowel Syndrome Treatment Product
7.8.3 Irritable Bowel Syndrome Treatment Sales, Revenue, Price and Gross Margin of GlaxoSmithKline plc.
7.9 Ironwood Pharmaceuticals, Inc.
7.9.1 Company profile
7.9.2 Representative Irritable Bowel Syndrome Treatment Product
7.9.3 Irritable Bowel Syndrome Treatment Sales, Revenue, Price and Gross Margin of Ironwood Pharmaceuticals, Inc.
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF IRRITABLE BOWEL SYNDROME TREATMENT
8.1 Industry Chain of Irritable Bowel Syndrome Treatment
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF IRRITABLE BOWEL SYNDROME TREATMENT
9.1 Cost Structure Analysis of Irritable Bowel Syndrome Treatment
9.2 Raw Materials Cost Analysis of Irritable Bowel Syndrome Treatment
9.3 Labor Cost Analysis of Irritable Bowel Syndrome Treatment
9.4 Manufacturing Expenses Analysis of Irritable Bowel Syndrome Treatment
CHAPTER 10 MARKETING STATUS ANALYSIS OF IRRITABLE BOWEL SYNDROME TREATMENT
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
